Nasdaq - Delayed Quote USD

Janus Henderson Global Life Sciences Fund (JFNSX)

66.38 +0.06 (+0.09%)
At close: 8:00:45 PM EST

Top 10 Holdings (40.85% of Total Assets)

SymbolCompany% Assets
LLY
Eli Lilly and Company 8.47%
UNH
UnitedHealth Group Incorporated 6.87%
NOVO-B.CO
Novo Nordisk A/S 4.65%
AZN.L
AstraZeneca PLC 3.66%
ABBV
AbbVie Inc. 3.61%
AMGN
Amgen Inc. 3.24%
SAN.PA
Sanofi 2.78%
MRK
Merck & Co., Inc. 2.57%
BSX
Boston Scientific Corporation 2.52%
JNJ
Johnson & Johnson 2.49%

Sector Weightings

SectorJFNSX
Healthcare   100.00%
Real Estate   0.00%
Technology   0.00%
Utilities   0.00%
Industrials   0.00%
Energy   0.00%

Overall Portfolio Composition (%)

Cash 0.02%
Stocks 99.14%
Bonds 0.00%
Others 0.65%
Preferred 0.15%
Convertible 0.03%

Bond Ratings

US Government 0.00%
AAA --
AA --
A --
BBB --
BB --
B --
Below B --
Other --

Equity Holdings

Average JFNSX Category Average
Price/Earnings 0.03 24.55
Price/Book 0.18 5.28
Price/Sales 0.35 2.06
Price/Cashflow 0.04 17.54
Median Market Cap 81,683.21 34,862.81
3 Year Earnings Growth 3.62 32.48

Bond Holdings

Performance & Risk

YTD Return 6.16%
5y Average Return 8.43%
Rank in Category (ytd) 29
% Rank in Category (ytd) --
Beta (5Y Monthly) 0.70
Morningstar Risk Rating

Fund Overview

Category Health
Fund Family Janus Henderson
Net Assets 5.25B
YTD Return 11.61%
Yield 0.00%
Morningstar Rating
Inception Date Dec 31, 1998

Fund Summary

The fund pursues its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in securities of companies that the portfolio management believes have a life science orientation. In the fund's pursuit of companies with a life science orientation, the fund has a fundamental policy to normally invest at least 25% of its total assets in securities of companies that are categorized in the "life sciences" sector.

Related Tickers